Role of ADAMTS and BNC1 as Diagnostic, Prognostic, and Predictive Biomarkers in Pancreatic and Colorectal Cancer

Review Article

Abstract

Aggressive cancer such as pancreatic and colorectal cancer poses significant challenges for patient management due to late-stage diagnosis and therapeutic resistance. In lieu of this, several biomarkers, including those associated with aberrant DNA methylation are being investigated for diagnosis, prognoses, and therapeutic monitoring of these cancers. Several studies have reported that A Disintegrin And Metalloproteinase with ThromboSpondin motifs 1 (ADAMTS1) and zinc finger protein Basonuclin-1 (BNC1) gene methylation leading to gene expression/silencing has been associated with cancer progression, metastasis, and poor overall survival.

Keeping this perspective in context, the potential utility of these methylation markers in pancreatic (PC) and colorectal cancers (CRC) is being investigated. However, limited review articles on the role of ADAMTS and BNC1 gene methylation in PC and CRC have been published.

Therefore, this review aims to comprehensively curate literature on ADAMTS and BNC1 DNA methylation as a diagnostic, prognostic, and therapeutic marker in pancreatic and colorectal cancer. The review aims to provide understanding of the complex mechanisms underlying ADAMTS1 and BNC1 DNA methylation and their role as potential therapeutic targets for these hard-to-treat cancers.